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1.1 Structure and Function of the Heart 
The heart is the first functional organ in the developing embryo and it starts beating 
within three weeks after conception (Gilbert 2000; Sherwood 2004). The heart is 
about the size of a clenched fist and it is located in the thoracic cavity between the 
sternum and the vertebrae. It is divided into a right and a left half by the 
atrioventricular septum. Each half is further divided into an upper and lower 
chamber called the atrium and ventricle respectively (Sherwood 2004). An 
atrioventricular (A V) valve is positioned between each atrium and ventricle and a 
semilunar valve is located between each ventricle and the artery leading out from it 
(Starr and Taggart 1998). The heart valves help to maintain a one-way flow of blood 
(Van De Graaff2002). The structure of the heart is illustrated in Figure 1-l. 
AOr1d--------~ 
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(Sherwood 2004) 
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Figure 1-2: Longitudinal section of the heart, depicting blood flow through the heart. 
1.2 Cardiomyopathies 
Heart fai lure is defined as a clinical syndrome of effort intolerance that is associated 
with fluid retention due to cardiac dysfunction. Heart failure is a major public health 
problem throughout the world (Seidman and Seidman 2001). In Europe, 50 million 
of the population of 1,000 million sutTer from heart failure, and in the USA, 4.9 
million patients are treated for heart failure each year (Moolman-Smook et al. 2003). 
In South Africa, similar statistics are not available however the Medical Research 
Council (MRC) reports that deaths from all forms of cardiovascular disease (CVD) 
account for 17% oftOlal mortality (Bradshaw et al. 2003). 
HeaJt failure may be either ischemic or non-ischemic in origin. The cause of a 
significant proportion of non-ischemic heart failure is cardiomyopathy (Moolman-
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(John et a!. 2004) 
Figure 1-3: A, A short axis slice of a heart with ARVC. YeJJow streaks of fat are 
indicated with arrows. B, A MRl of the same slice, which shows an increased signal 
intensity corresponding to the yellow streaks seen in A. C&D, A histopathology 
specimen taken from the RV showing large numbers of fat cells. LV = Left 
Ventricle, RV = Right Ventricle 
1.2.5 Unclassified Cardiomyopathy 
Cases that do not fit into any of the above mentioned groups, e.g., isolated left 
ventricular non-compaction (L VNC), fall into the group unclassified cardiomyopathy 
(Richardson et a!. 1996; Hughes and McKenna 2005). 
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Figure 1-4: Desmosome ultrastructure and molecular model in human skin. 
8 
r - -) OESIoIOOl£IN PlAKOPHILIN 
C--:J oeSIIOCOWN DESMOPLAKIN 
_ PUlKOGL061N KERATIN 
A, An electron micrograph of a desmosome in human skin, showing the regions of the junction, namely: the inner dense plaque (lOP), the outer 
dense plaque (ODP), the plasma membrane (PM) and the dense midline (DM). B, A molecular model which depicts the relative organisation of 
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a 0.5cm wide spacer in between. The plates were set upright with the wells at the 
bottom. Figure 2-1 illustrates the set up of the plates. 
back plate 
Figure 2-1: Set up of plates for polyacrylamide gel 
A polyacrylamide gel was prepared by mixing 17ml 8% polyacrylamide solution 
(Appendix 2) with 200111 10% ammonium persulphate (APS) and 20)11 N'N'N'N'-
tetramethylethylenediamine (TEMED) (BDH Laboratory Supplies). APS and 
TEMED cause polymerisation of the polyacrylamide solution, therefore this mixture 
was quickly poured between the plates using a 10 ml syringe. The gel was allowed 
to polymerise for approximately an hour before use. The clamps were removed, the 
plates separated and the back plate (containing the gel) was put into position on the 
"Multiphor II Electrophoresis System" (Amersham Pharmacia Biotechnology, 
Separation Scientific). Six filter paper strips (5cm x 28cm) were soaked in I x TBE 
(Appendix 3). Three strips were placed on both the top and bottom of the gel. A 
volume of 3)11 PCR product was mixed with 3)11 agarose loading dye (Appendix 3) 
of which 3)11 was loaded into the well. The PCR products were electrophoresed 
through the gel at approximately 355V for two hours alongside a I kb Plus DNA 
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Ta ble 3-1: A summary of the sequence variants identified in the LAMRJ gene 
SV number Nature of cbange SNP accession number Physical location 
SV 1 C>G 11717-U9 ~847 
SV 2 G>A 3771147 1859 
SV 3 C>A - 2861 
SV 4 20bp deletion - 2934 2953 
SV 5 C>T 3772 146 3UnO 
SV 6 f">C 3771144 3210 
SV 7 G>A - 3852 
SV 8 T>C 1803g9] 3933 
SV 9 A'>G 3772141 4237 
sV 10 C> J 3772138 4861 
SV 11 C>T - 4993 
SV 12 T A insertion - 5075 5076 
SV 13 G>A - 5158 
SV 14 A>G 2077798 6901 
SV 15 A>C - 7005 
SV 16 I G>A 2269350 7956 
SV 17 C>T 2723 8 .. H)6 
Note: SVs are numbered in base pairs relative to the genomic sequence in Appendix 
5. SVs recorded in the NCBI SNP database are highlighted in red. 
SV 14 SV 16 
1 E4 E6 E7 
I" ... t tl 12 iJ 14 15 IG ' u 
--{}--/~ HH~l ~. Hf-D-IL tin :-
r """ """t "'" r" "'" r 
SV 1-5 I i 
SV 7 SV 9 I SV 13 
246bp 
649~ IIBbp 2~30p 
129bp Hi6bp 1 61 bp 
SV 15 
SV 11 SV 17 
(Jackers et al. 1996) 
Figure 3-1: Schematic diagram of the LAMRJ gene illustrating the location of the 17 
sequence variants. E = exol1, I = intron 
50 
University of Cape Town
Table 3-2: The LAMRJ sequence variants found in each patient 
SV 1 SV2 SV4 SV5 SV6 SV 7 SVS SV 9 SV 10 SV 11 SV 12 SV 13 SV 15 SV 16 
ACM 1.2 KEV 1 1 1 1 1 1 
ACM 2.4 MRC 1 1 1 1 1 1 
ACM 3.1 CHE 1 1 1 1 1 1 1 1 1 1 
ACM 4.1 ROS 1 1 1 1 1 1 1 1 1 1 
ACM 5.1 JOH 1 1 1 1 1 1 
ACM 6.1 HAV 1 1 1 1 1 1 
ACM S.3 MIC 1 1 1 1 1 1 1 1 1 1 
ACM 9.1 POU 1 1 1 1 - 1 1 ACM 10.1 HIL 1 1 11 1 1 ACM 11 .2 JON 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 11 ACM 12.1 HER 1 1 1 1 1 1 1 1 
ACM 13.1 JOH 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
ACM 14.1 DER 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
ACM 15.1 VIG 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
ACM 16.1 HEN 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
ACM 17.1 AKH 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
ACM lB .1 T1A 1 1 - 1 1 1 1 1 1 1 1 ACM 19.2 CHR 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 ACM 20.1 ENA 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
ACM 21 .1 COL 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 11 
ACM 22.1 AND 1 1 - 1 1 1 1 1 1 1 1 ACM 23.1 GAM 1 1 1 1 1 1 1 1 1 1 
I = the wild type sequence (according to NBCI accession no. NT _022517.16), 2 = the sequence variant 






























C A G A CA T _.\1 A ::-l' A G A AGACATAGAAA (wild type aJlele) 
f\ A AA .~ . A + AGACATA T AGA (allele containing TA insertion) 
ill l~  ~ = AGACAT AKARA (sequence ofheterozygolls patient) 
Figure 3-3: A, A patient with wild type sequence (according to NBCI accession no. 
(NT _ 022517.16). B, A patient homozygous for the T A insertion. C, A patient 
heterozygous for the T A insertion. The derivation of the sequence for this patient is 
given alongside. 
To determine the effect of SV 3, 7, 11, 13 and IS on splicing, Splice Site Prediction 
by Neural Network was used which is available on the Berkeley Drosophila Genome 
Project website (www.fruitfiy.org/seg tools/splice.html). The splice sites could not 
be determined for the sequence surrounding SV 3 and 15. SV 7, 11 and 13 were 











3.2 PAGE Analysis 
The SV 4 (20bp deletion) found in patient ACM 9.1 POU was also detected in 2 
unaffected family members and in 3/65 ethnically matched population controls (i.e. 
Caucasian South Africans), suggesting that it is common polymorphism with a 
carrier frequency of 4.6%. The three controls, with the variant profile on PAGE, 
were sequenced to confinn the presence of the 20bp deletion. The pedigree of 
patient ACM 9.1 POU is illustrated in Figure 3-4 along with the family genotyping 
results. 
A B 
L 11:2 11:1 1:1 1:2 
11 l2 
IT 1 IT2 
Figure 3-4: A, Pedigree of family 9. B, Genotype results for SV 4 in family 9. 
Pedigree numbers are indicated above each lane. The DNA fragments with the 20bp 



























Figure 3-5: Haploblock type definition by the A, confidence interval method and B, 
solid spine of LD method. Strong linkage disequilibrium (LD) between markers is 























4 METHODS: MUTATION SCREENING OF 
THE CBX5 GENE 
4.1 Patients 
The patient cohort described in "Methods: Mutation Screening of the LAMRl Gene" 
was screened for mutations in the CBX5 gene. Controls were used in the dHPLC 
screen. They were of Caucasian and black African descent and were archived in the 
Division of Human Genetics, UCT. 
4.2 peR 
4.2.1 Primer Design 
Primer pairs were designed for exons 2 to 5 of CBX5. The sequence of these primers 
is given in Table 4-1. Exon 1 was excluded from this mutation screen as it is not 
translated. The disease model, described by Asano and colleagues, was due to Hpl 
binding specifically to mutant Lamr 1 (Asano et aI., 2004). The hypothesis was 
therefore to screen exons encoding CBX5 protein for mutations that might lead to a 
greater affinity ofCBX5 for LAMRl, and so lead to ARVC. ANNOTV9 and Primer 
3 were used to design primers. OligoAnalyzer 3.0 and Basic Local Alignment 
Search Tool (BLAST) were used to evaluate the primers. 
OligoAnalyzer 3.0, a program freely available on the internet 
(http ://sci tools. idtdna.com/sci toolsl Appl ications/O ligoAnalyzer/Defaul t.aspx), was 
used to identify possible: 
1. Hairpin structures: annealing of the primer with itself 
2. Homo-dimers: annealing of primers of the same type 
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dG = -0.6 20_Base_Oligo 
HOHO-DIHER ANAl. YSI.S 
Dime. s.q_ .. ce 
5 '- CACAIGGCAACTCAGIGIU - 3 ' 
M"';mum D.ttA CO -~ .4 k.cAVmol. 
Dotita CO - ' .38 kn Vmol. 




P ...... ry s.quen.,. 
5' - CACA!GGCAACTCAGTGTIA -3' 
s.cond.ry Sequence 
5'- CTCTTkGGAAGAGTGCAGGAG -3' 
M"';mum D.tb CO -36.87 k.cA Vmol. 
D ...... CO - 5 .09 k.cAVmol. 




Figure 4-1: Secondary structure prediction by OligoAnalyzer 3.0. A, Hairpin 
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Table 5-1: Summary of the CBX5 exon 3 DHPLC screen 
Patients Methods (in °C) 
55.7 54.7 52.7 
ACM 1.1 KEV * ., ., 2 
ACM 2.4 MRC ') .., ') 
ACM 3.1 CHE I I I 
ACM 4.1 ROS 2 ., 2 -
ACM 5. 1 JOII* 1 1 I 
ACM 6.1 IIA V 1 1 I 
ACM 8.3 MIC* 
.., ... ... 
) -' J 
ACM 9.1 POU 3 3 ... J 
ACM 10.1 HIL 1 1 1 
ACM 11.2 JON 1 1 I 
ACM 12. 1 llER 
., 
'" 3 .J .J 
ACM 13 .1 JOH .., 2 2 
ACM 14.1 DFR ., ., ., 
ACM 15. 1 VIG I ., ., -
ACM 16.1 liEN ') ') 2 
ACM 17.1 AKII I ') ., 
ACM 18.1 TlA ., ') ') -
ACM 19.2 CIIR .., 2 , 
ACM 20.1 ENA ') , , 
ACM 21.1 COL ') ') ') 
ACM 22.1 A 0 ... 
.., ... 
-) J J 
ACM 23. 1 GAM I ., 2 
Note: 1 = wild type profile, 2 = aberrant profile, 3 = spurious profile 
Patients with the same chromatographic profile at all three WAVE methods are 

































Figure 5-1: Chromatograms of ex on 3 @ 55.7 DC indicating A, wild type profile B, 











5.1.2 Exon 4 
Minor differences In chromatographic profile were observed in two out of four 













Figure 5-2: Chromatograms of exon 4, patient ACM 3.1 CHE and control (can 11.1) 
at A, S7.SoC and B, S5.2°C. Minor differences between control and patient profile 
are indicated. 
70 
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5.1.3 Exon 5 
Differences in chromatographic profile were observed at all three WAVE methods in 
patient ACM 19.2 CHR. These chromatograms are given in Figure 5-3. DNA for 
this patient's affected sibling (ACM 19.1 TRE) was archived in the Division of 
Human Genetics, UCT and was subsequently screened for this exon. The sibling did 
not have the same chromatographic profile as the patient and the polymorphism was 
therefore concluded not to be disease causmg. 
chromatograms are given in Figure 5-4. 





e¥-__ ~ ________ ~ ____________ ~~ __________________________ ~ 
o 2 
Trno (IJlflUtes I 
Figure 5-3: Chromatograms of exon 5, patient ACM 19.2 CHR and control (con 
12.1) at all three WAVE methods 
71 
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Figure 5-4: Chromatograms of exon 5, patient ACM 19.2 CHR, sibling ACM 19.1 
TRE and control (con 12.1) at all three WAVE methods 
5.2 DNA Sequencing 
5.2.1 Exon 2 
One sequence variant, a T to C substitution, was identified in exon 2. It is reported 
as a SNP on the NCB! SNP database (accession no. 1140681). Seven patients were 
homozygous wild type (according to NC_000012.9) (i.e. TIT), ten patients were 
heterozygous for the variant (i.e. TIC or Y) and five patients were homozygous for 
the variant (i.e. CIC). The status of each patient for the SNP is shown in Figure 5-5. 
Sequencing with the forward primer did not produce good quality sequence. 
72 
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CIllo 121 








































..... .... ... ... ... ...... ... Y. . . . .. •• .. • . . • 
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· .... . . •• •.• .. . ... . • . ... • •• c .. . ... • .. • . . • 
· .... . . .. ... ... ... . . . .... .. C .. . .. .. .. . . . . 
· .... . . .. ... ... ... . . . ... . .. c .. . .. .. .. . . . . 
· .... . . •. ..• ... ... . . . ... ..• Y. . . . ... • .. • . . • 
I· ···· · · ·· ··· ·· · ··· · · · ··· ··· Y. ·· · ·· ·· ·· · · · · · .... . . •• ..• .•. ... . • • .... •• Y. . . . .. •• .. . . . . 
· . . . . . . .. ... ... ... . .. ...... Y. . . . .... .. . . . . 
· . . . . . . . • . . . . . • . . . . • • . . . . .. Y. . . . . . .. .. .. . . 
· . . . . . . .• ... . .. ... ....... .. Y. .• . ... . .. • . . • 
· . . . . . . .• ... .. • ... • • • ... . .. Y. .. . .... .. . . . . 
• • • . • • • •• ••• •• • ••• • • • •••• •• C •• • •••• •• • • • • 
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· . . . . . . . . . . . . . . . . . . . • . . . . .• Y. .. . .... .. • . . . 
· .... . . . . ... .. . ... . . . ... ... c . . . .... .. . . . . 
Figure 5·5: Part of the alignment between the reverse sequences and the wild type 
sequence which shows the status of each patient for the SNP. 
5.2.2 Exon 3 
The sequence variants were not identified in exon 3 as sequencing with either the 
forward or the reverse primer produced sequence of poor quality. 
5.2.3 Exon 4 
No sequence variant was identified in patient ACM 3.1 CHE upon sequencing. The 
minor differences in the chromatographic profiles were therefore not indicative of a 
variant. 
5.2.4 Exon 5 
The sequence variant in ACM 19.2 CHR was not identified as sequencing with either 
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A total of 17 sequence variants were identified in LAA1Rl and they were named SV 
1-17. Of these variants 10 (i.e., SV 1, 2, 5, 6, 8,9,10,14,16 and 17) were reported 
as SNPs on the NCBI SNP database. None of the seven novel variants (i.e., SV 3, 4, 
7, 11, 12, 13 and 15) were predicted to have a pathogenic effect on protein structure 
or function, although this remains to be confinned in functional studies for some of 
the variants. 
SV 3 is a single base substitution in the promoter region of LAMR1, 140bp upstream 
to exon 1. The possibility that this variant, which occurred in 4 patients, affects 
transcription has not been excluded in this study. Four variants, namely SV 4, 7, 11 
and 15 were identified only once and each time in a different patient. SV 4 was 
found to be a common polymorphism with a carrier frequency of 4.6% in the 
background population. SV 7, 13 and 15 are intronic sequence variants and SV 11 is 
an exonic variant that does not change the amino acid. SV 12 was homozygous in 
one patient with apparent recessive ARVC but heterozygous in unaffected and 
affected family members. SV 12 was therefore thought not to be disease causing. 
To detennine the effect of SV 3, 7, 11, 13 and 15 on splicing, Splice Site Prediction 
by Neural Network was used which is available on the Berkeley Drosophila Genome 
Project website (www.fruitfly.org/seqtools/splice.html). The splice sites could not 
be detennined for the sequence surrounding SV 3 and 15. SV 7, 11 and 13 were 
predicted not to interfere with splicing . . 
For SV 4 (20bp deletion) and SV 12 (2bp insertion) the exact bases deleted or 
inserted could not be determined. According to the Human Genome Variation 
Society (HGVS) " the most 3' position possible is arbitrarily assigned to have been 
changed". The 20bp deletion, 292ltctccggctc cgcccttctt ccgctcgact ttctttgcca to 
tctccggctc cgctttgcca, is therefore indicated in Appendix 5 as 2934_29S3de120 and 
not as 2933 2952de120. The 2bp insertion, 5071acatagaaag to acatatagaaag, IS 
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Tme (J,h MH) 
Figure 6-1: Chromatograms of exon 2, control samples con 11.1 and 12.1 
6.2.3 Sequencing 
Difficulties were experienced in sequencing LAMRl exons 4, 5 and 6 as well as 
CBX5 exons 2,3 and 5. 
AnaJysis of the sequence obtained for LAMRl exon 4 revealed that the wrong 
genomic sequence had been sequenced. Inspection of the exon 4 primers revealed 
that the forward primer was designed over a region that contained two SNPs. One of 
the SNPs was situated 2bp from the 3' end. The exon 4 primers were subsequently 
redesigned and named LAMRI_ 4bF & R. 
Exons 5 and 6 were amplified in one amplicon. The sequence obtained from the 5+6 
amplicon was of good quality lmtil after a stretch of 10 "1" bases. This is illustrated 
in Figure 6-2. According to an online guide to sequencing by Hill and Helps 
(Chapter 8, Online resources), Taq DNA polymerase is not able to efficiently read 
through homopolymeric stretches of bases due to its lack of processivity. When Taq 
DNA polymerase reaches a homopolymeric stretch of bases one of two things can 


















premature loss of signal strength, or it can "slip", which results in high background 
after the homopolymeric region. The latter appears to be the case in sequencing of 
ampJ icon 5+6. This did not however pose much of a problem as the 10 "T" bases 
were situated in the intron between exons 5 and 6. Exon 5 was therefore sequenced 
with the forward primer and exon 6 was sequenced with the reverse primer. 
A 
330 34& 
C TTT CC T C ITIITTTTTT G W A ~ C C :\f A 
B 
360 370 3sn 
R TTT R C T R TTITITITTT G T AA CC C A 
Figure 6-2: Sequence obtained for one patient where sequencing was performed 
with A, LAMRl_5+6F and with B, LAMRl_5+6R. The same stretch of sequence is 
shown; the reverse sequence has been reverse complemented by BioEdit. 
Poor sequence quality was obtained when sequencing was perfonned with primers 
LAMRl_ 4bR, CBX5_2F, CBX5_3F&R and CBX5_5F&R. The sequence obtained 
for CBX5 exons 2 and 3 is shown in Figure 6-3 and 6-4 respectively. These primers 












2:0 no 160 
o 0 0 G ." .-\ . ' 0 0 ~ T T r .. C ~ ~ A G • .\ ~ ~ • •• e e l 1 
B 
180 290 300 
G T OG A .-\ A GG C -rTTT C T O A O T A AG TT C C TTT 
Ufjwrn'~J~ytil~ 
Figure 6-3: Sequence obtained for one patient where sequencing was perfonned 
with A, CBX5_2F and with B, CBX5_2R. The same stretch of sequence is shown; 
the reverse sequence has been reverse complemented by BioEdit. 
A 
150 
G G :-I 0 0 
B 
1 160 
G "j O A'-\'-\ '-\ T .-\.-\ T A A . · C 
I 0 
C CGGGG ~ G .~ A 
ISO 19{) 200 
o 0 .-\ 0 G G T 0 .-\ A .-\ A T .-\ A T .-\ .-\ .-\ C C C ~ GOO A G .-\ .-\ 
Figure 6-4: Sequence obtained for one patient where sequencing was perfonned 
with A, CBX5 _3F and with B, CBX5 _3R. The same stretch of sequence is shown; 
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8 ELECTRONIC RESOURCES 
BLAST search on NCB! 
http://www.ncbi .nlm.nih.gov/bJastl 
Hill AJM, Helps, NR (2000) A Guide to Automated DNA Sequencing v 1.2. 
hUp:llwww.dnaseq.co.uklDownloadsisequencing guide.pdf 





http://frodo.wi .mil.edulcgi-biniprimer3/primer3 www.cgi 
Splice Site Prediction by Neural Network available on the BerkeJey Drosophila 
Genome Project website 
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Appendix 4: DNA Ladders 
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Figure 9-1: 1 Kb Plus DNA Ladder. A volume ofO.7)lg of DNA ladder was 
electrophoresed on a 0.9% agarose gel. 
bG notO.5JIJ " 
3000 77.8 15 6 
2000 55.0 11 0 
1500 39.2 78 
1200 33.0 66 
1031 33.6 6.7 
m ~J ~~~ 
~ ~~:1 1 3J 
~!. ~o 
3(M) 25.0 5.0 
200 25.0 50 
100 250 5 0 
Figure 9-2: GeneRule?M lOObp DNA Ladder Plus. A volume ofO.5)lg of DNA 
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2521 aacttccctt aagtgaacat ttaaatctga attacgtcct gttaaactgt tctccaggaa 
2581 aataaaataa aataaatctt caagtttttg tttacctaac aatttgttgt gtcgaacaaa 
2641 ccttcctact tttcaggtaa caaaatggca gcttaggcta gaaagccgct catattcgca 
2701 ggtacaaggg ctgggtaaga acgccccgcc tggctgacta acttgagttc cgcgctctgg 
2761 acaggaatta tgcacagggc gtcgctgtgg cactagaaac cccaaagtca caagcgcccc 
2821 agatccgacc aggatgccgc tac~cgg Actac agccca~ga 9 ccgctcctg cggcgcaagc 
(2844) (c/g) (dbSNI?:1l925942), SV 1 2847 cl dbSNE' : 1l717439) , 
2881 
2941 
(2857) (a/g) (dbSNt':1l926001), 
LAMR1-Exon1(3001-3051 -> 51bp) 
cgc Accttctt 
atttcc tgc 
3001 GCCTGTCTTT TCCGTGCTAC CTGCAGAGGG GTCCATACGG CGTTGTTCTG Ggtgagttcc 
3061 gtgtagcgtc cctggcgcct cttttcctgc tcaaatgaag 
3121 ggtgagaaga ctagtgatga ctcccgcc cggcgcgccc 
3181 caccttaggc ctgcggcccg cacgtg cca ttcc cagagtgccc 
(3215) (c/t) (dbSNI?:3772145), 
3241 cgggagcggg tggaggccgc cctccagcgg aggctccgag ctggggttcg gaccaggccg 
3301 cgggtgggcg ggagtgcaga aagcgggcta acatcctgtg ttgctatccc ttcggagtcc 
3361 cacacggcgg tgagtc~tagg cccaggcgct gatttacacc agctacttgg gctgg~tcggg 
(3377) (t/g) (dbSNI?:3772143), (3416) (c/t) (dbSNI?:1l706951) 
3421 ttttcccttc gcgccgtgcg ggtcaggagt taaggttctc gggtttttag acaaacaagt 
3481 ggtgacagca cagcgaagta attccaaagc atccgcctac aatctgc~ttg aaaatgtctg 
(3528) (a/t) (dbSNI?:3772142) 
3541 aaaacaattc atgccttttt tgcctttagt ttgcatattc caaacatggc tgctctttt~g 
(3600) (a/g) (dbSNP:1472508) 
3601 tatctagttg ttaacttggc gcatccacaa cttttcctta attcctatct tgagaagtgt 
3661 tgaatttcca ttcgctaatt tcgtgtagtt ttattactcg gttactctgc cgtccacact 
3721 atttcctcag taagatgtgc gctgttccgt aatacacgac atgtatgggt taactttctg 
3781 tttacccttc actacactgt aagctcaatg cctgacacta tagcagatgg agtttttggt 
3841 tgcttttaag g Ag tgtgccct acttaactca atggaatgaa aagaaatagg ttgctctctt 
SV 7 (3852) (g/a) 
LAMR1-Exon2(3908-4073 -> 166bp) 












ATGTCCTTAA GTTCCTTGCA GCAGGAACCC ACTTAGGTGG 
TGGAACAGTA CATCTATAAA AGGAAAAGTG ATGgttagtc 
ctccagctgt aagtacaaat tttgagcttg ctattctcgt 
tttctatctt ccttaaatga agccagaccc ctacgttgaa 
tcttgttatt gagaga aag atttctgctc caggggagga ------a aataaatgt 4261 atatgtcagt tgtctgagtt acgggacttg ggttgggtca tgaacatgag aaagttcatt 
4321 ggctgagttt ctaatagctc gcatagtgcc ttcaacttca taggtactta cacaggctat 
4381 tgaactgaat tttgagtgga aagtggggta agaggtggga atgaacaata tggtttggaa 
4441 gaaccagagg atggaaggca ttaagttggc taaggcactt acttatttta gagataaagc 
4501 taccaaggac ttgggagtga catgctgtaa aggagtttta ggatgaatct tgcatcagtg 
4561 cagat~tataa aagggaaaga gtggcagaaa gccaggaagt ggattAattaa gaaccaatga 
(4566) (t/g) (dbSNP:3772140), (4606) (a/c) (dbSNP:3772139) 
4621 tggaataagt acagggaaag agaaaggaaa gatggattta 
4681 acactattaa agctcagggt ggaggccagt cttggctcat 
4741 tgtgctatat caatggcagg attttcgcta acaccagtag 
4801 gtttggtagt actcgctgcc acatagagta aacttgagaa 









4861 Acaagtgttac aaatccttct gccctcactt agGCATCTAT ATCATAAATC TCAAGAGGAC 
SV 10 (4861) (cit) (dbSNP : 3772138) 
4921 CTGGGAGAAG CTTCTGCTGG CAGCTCGTGC AATTGTTGCC ATTGAAAACC CTGCTGATGT 
4981 CAGTGTTATA A ATACTGGCCA Ggtttgtgga acagtggtta gtttttatat 











5101 ctcaggccgg gcgcggtggc tacgcctgta atcccagcac tttgggaggt ggagtcc ~ggc 
SV 13 (5158) (g/a) 
5161 gtattacgag gtcaggagat ccacaccacg gtgaagcccc atctctacta aaaatacaaa 
5221 aaattagttg ggcgtggggg cgggtgcctg tagtcccagc tactcaggag gccaa~agtgg 
















agaatggcgt gaacccggtg ggcggagctc 
agcctgggtg acagagccga gactctgtct 
caaactccac tgttaagaga tcttaagttg 
tatgaccttc cttttttttt tttttttttt 
gcctgttgtc catcctggac tgcagtggtg 
taagctcaag ggattctcct gcctcatcct 
accatgcctg actgattttt gtatttttag 
tggtcttaaa cgcctgatct caagtgatcc 
tacaggcg[a agccactgcg cccagcctgt 
tggcagtatg ttgaacttta taatttcatt 
aaattctatt aaagtggctt atcacatttt 
tgaaatactg ggacagaaat tttttaagaa 
agttcccgtt aattgggagt ctgagccagg 
cagtaagtta tgattttgcc actgcactcc 
cttaaaa~aag ccagtcatgg gtggctcatg 
(6128) (a/c) (dbSNP:11921564) 
gcagtgagct gagatgcgcc actgtactcc 
caaaaaaaaa aaaaaagaaa atagaaaact 
gactgagcca tagaaatcgc ccttatgacc 
ttttccttca agacagtctc tcgctctgtt 
tgatatcggc tcattgcagc ctttgcctcc 
cccgagtagc tggaattaca ggcatgtgcc 
tagagacatg gttttaccat ttggccaggc 
tcccacctcg gcctcccaaa gtgttgggat 
aagacctttt caacatacat gctgggcatc 
ttgtgtagac ttgtgccact aaatatctag 
cccatagtca aagtttttac cttaaaacaa 
tcttagccag tcatgacggc atgcacccat 
agatccctca agtccaggag ctgggggctg 
aagcctgggg cacagagtga gatcctgttt 
cttttgtaat atggggtact ttgtgaggct 
6181 gaggctggtg gcttgcttga gcccagaagt tcgagaccag ggtgggcaac gtggcaaaac 
6241 tccgtctcta ccaaaattaa caaaaacgag ctgggtgtgg tgttggcgtg cctgtagtct 
6301 cagctgaggc t~aaggtggg~a agattgctag aacacaggag gttgaggcag cagggagcca 
(6312) (a/g) (dbSNP:7619128), (6320) (a/g) (dbSNP:7619131) 
6361 agactgtcca ctgcatccca gcctgagtga cagagtgagg ccttgtctca aagagaacct 
6421 ctgccaactt gaatgaaaaa taccttaatt tgtattttta agaaatgact agttagtaaa 
6481 acttgaatct tttttgccac agctcta~ttt taataatttt ~tctgttgaga aaactagtag 






atttcttgaa ttctaagagt tctaacaggg 
ttaaaaatta tgtagtaaga ctttatttca 
tttgcagagg gttattcctg aaactgactt 
tagaaaaaag gcagttagtt attgctgtag 
gagaaaaata tactgagcat ctagattggg 
(6834) (a/g) (dbSNP: 1318417) 
attttattca tcttaactat tttgacagat 
atgttgacag gacgggttcc catgtgtgtt 
gttactagga ccacatagtt tggtacacag 
aatgaactga gtgacagttc ttgcttgctt 
ccaggtagtg ttgctaggtg ctc~gggatat 
6841 a ca gtagaaa aacaagcctg tcttttttaa tgtatgcagg aaatctctgg agaagtaaga 
6901 9 ggtt a a gg aaagct gg ~ gt at gt~ gcctgc tttacatgga gtagtagtga ttaagttggc 
(6919) (a/g) (dbSNF:2077797), 
(6925) (t/g) (dbSNt':2077799) 
6961 cagtgc c c a g aagt g cttac tgggtgccag gattgttgct gtgg atatc gagtac~cact 
(7017) (branch slte - YNYYRAY) 
LAMR1-Exon4(7041-7286 -> 246bp) 
7021 aacttttaaa ttcttcaaag AGGGCTGTGC TGAAGTTTGC TGCTGCCACT GGAGCCACTC 
7081 CAATTGCTGG CCGCTTCACT CCTGGAACCT TCACTAACCA GATCCAGGCA GCCTTCCGGG 
7141 AGCCACGGCT TCTTGTGGTT ACTGACCCCA GGGCTGACCA CCAGCCTCTC ACGGAGGCAT 
7201 CTTATGTTAA CCTACCTACC ATTGCGCTGT GTAACACAGA TTCTCCTCTG CGCTATGTGG 
7261 ACATTGCCAT CCCATGCAAC AACAAGgtaa tgattttagg atctagagtt tgtgaatgcg 
7321 tgctctagaa aaaacattcc tgtgcacatt gttagagctt ggagttgagg ctactgactg 
7381 gccgatgaac tcgcaagtgt aggtagtgtg ctacatgagg ggcaagtttt cgctaacacc 
7441 acaagggtct ctggcccaat gagtggagtt tgatagtaat tcttgctaca agtacaacat 
7501 tactgcatga cagctttgtg gagaaatgaa aacatttgga aaatagtgtg ttcttctgcc 
7561 tttgtcc~atg tttcttgctc aggcctcagg cacttggcct ttgttttcac accaacttga 
(7568) (a/g) (dbSNP:1392192) 
7621 tgggttctac tataagatgc taaaaaggtg ggttgtgtgt ggttcagatt ggttgatttg 
7681 taaccctagt tgtgcataag aattgcccag atattttttt taaatgccag tgtccaggca 
7741 tttttttttc aatccctatg attccagtgt gcagacaagg ttgaaaatcc ctat~tataa 
7801 tgctccctgt tacaattgct tttcaactaa gagatgtctg tacttttggt ac~ctagatga 
(7853) (c/t) (dbSNF: 2269349) 
7861 tgtaagagcc aggaaggtgc ttgctgtttg ggtttgacca agtgtcact~t tttaataatc 











LAMRI-Exon5(7936-8064 -> 129bp) 
7921 tgccactctt ggcagGGAGC TCACTCAGTG GGTTT AGATGT GGTGGATGCT GGCTCGGGAA 
SV 16 (7956) (a/g) (dbSNP : 2269350) 
7981 GTTCTGCGCA TGCGTGGCAC CATTTCCCGT GAACACCCAT GGGAGGTCAT GCCTGATCTG 
8041 TACTTCTACA GAGATCCTGA AGAGgtaagc ttctccaaag gcttgtggtt acataagcaa 
8101 attggacgac ttggactgtg cttctaggaa gcaaaacttg tcagtccctg taagtctttc 
LAMRI-Exon6(8183-8348 -> 166bp) 
8161 ctcttttttt ttAtgtaaccc agATTGAAAA AGAAGAGCAG GCTGCTGCTG AGAAGGCAGT 
(8173) (branch site - YRYRAY) 
8221 GACCAAAGGAAG GAATTTCAGG GTGAATGGAC TGCTCCCGCT CCTGAGTTCA CTGCTACTCA 
(8227-8498) (STS:Rt' SA_I), (8229-8474) (STS:G59752) 
8281 GCCTGAGGTT GCAGACTGGT CTGAAGGTGT ACAGGTGCCC TCTGTGCCTA TTCAGCAATT 
8341 CCCTACTGgt atgtatcagg atagaggtga atcaagctga tattttgcaAa cttctcagtt 
(8390) (a/g) (dbSNt':2276714) 
8401 actt ttatactagc tttaagaggt tttcattcca 
8461 gtgtgctaca gcatctgata gactgctgtt ggAgagtgggg taaggaaaaa tactacattg 
(8493) (t/g) (dbSNt':7635671) 
Lfu~RI-Exon7(8561-8721 -> 161bp) 
8521 aggacagagc tgatggcttt ttttggtatt cAtcttaacag AAGACTGGAG ACAGCTCAGCCT 
(8552) (branch site - YNYYRAY), (8571) (c/t) (dbSNt':2724), 
(8572) (a/g) (dbSNt':2725) 
8581 GCCACGGAAG ACTGGTCTGC AGCTCCCACT GCTCAGGCCA CTGAAATGGGT AGGAGCAACC 
(8625-8788) (STS:RH92628) 
8641 ACTGACTGGT CTATAAGCTGT TCTTGCATAG GCTCTTAAGC AGCATGGAAA AATGGTTGAT 
stop 
8701 GGAAAATAAA CATCAGTTTC Taaaagttgt cttcatttag tttgcttttt actccagatc 
8761 agaatacctg ggattgcata tcaaagcata ataataaata catgtctcga catgagttgt 
8821 acttctaaag cccactgtag atagtgtata ttgcttttca cttcagaatt tccctgagct 
8881 tccttcctgt gtggagaaca tgtgtgctgt gaaaatagat gtaagtggtt acacatactt 
8941 agttggtaac ctcaggaata cttttccAgag gccctgatga tcttgctttt attaccattt 
(8968) (c/g) (dbSNP:7638276) 
9001 gcgtaggtaa gttctataga gcttaggttt ttatttttga gagtcttcct gtcacttagg 
9061 ttaactattc ctggaagccc tggagaggcg atggtccttc cccacattga gagacattaa 
9121 ttgcccctct tgtcagcttg cctacaggtt ctgggagagg agaggtatgt atgtatttaa 
9181 aaatgtgatg ttctccatat ttgtctt gc cggggagggg gttggggaga cagtctttcc 
9241 ctgttgccca ggctggagta cagtggcgtg atctcagttc actgcaacct ctgcctcctg 
9301 ggttcaagcg attcttgtgc ctcaggctcc ttcgtagctg ggatttcagg tgtgcactgc 
9361 cacacctagc taatttttgt atttgtagta gagatggttc tgccaggctg gtctccaact 
9421 cctggcctca tgtgacccgc cccaaaatgc tgggattaca ggcctgagcc tgaccatatt 
9481 tgttttttat gtattaatgc tggtggcttc atcctaaacg gatttcaaga ttttcattgc 
9541 ctattaaaaa aatactcgtg gctgtcatgt tggctcaccc atgatcccag cactttggga 
9601 ggcagaggca aagcgattgc ttgagctcag gagttcagga ccagcctggg caaAtgtggta 
(9654) (c/t) (dbSNP: 13070037) 
9661 aaaccccatc tctctccaaa agatacaaaa aattggcagg gtgtgatggc atactcctgt 
9721 agtacctcag ctacacagga gactgaggtg ggagaatcac ctgaggccag gagttggagg 
9781 ctgcagtgag ctgtgattga gcccctgtat actctagcct gggtgacgaa gtgaggccct 
9841 gtctcaaaaa gattatagag acatttccat agattggatt gaatgcagat tttgagatgg 
9901 cctgaactga tttacatgga ttcatacatt ctcttggaaa atttacaaaa tacatgtaca 
9961 tgtgaccaca ttcctagggc tccttccggt ggtgctgagg caatgggaac actgcaAgcct 
(10017) (a/g) (dbSNP:7641291) 
10021 caagcattgt cttcatggga agcctgctta tggctgtaag cgaggctggg aaaatctgcc 
10081 ctataatgtc tccaagttga atggcattca Agtgagattta tggatcctga agttgcaagt 
(10111) (a/g) (dbSNt':12638378) 
10141 ggttagcaaAc actggtagag attgctggaa tcaggatggt gggaagcagg gacagtttac 
(10150) (c/t) (dbSNt':12638341) 
10201 cagaaggcta ctggAtcaaca ggggagttgg agaagcattg cgaggtggtg tgagcctgga 
(10215) (c/t) (dbSNt':7633878) 
10261 gtaaggtata ctaagctcat ttatgagcgg gttctgggtg gagtctgttc agAcgaacaga 
(10313) (c/t) (dbSNt':13095720) 
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